-
Product Insights
NewNet Present Value Model: Galmed Pharmaceuticals Ltd’s Icomidocholic Acid
Empower your strategies with our Net Present Value Model: Galmed Pharmaceuticals Ltd's Icomidocholic Acid report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewPrimary Sclerosing Cholangitis – Drugs In Development, 2024
Empower your strategies with our Primary Sclerosing Cholangitis – Drugs In Development, 2024 report and make more profitable business decisions. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs. The Primary Sclerosing Cholangitis drugs in development...
-
Product Insights
NewCholangitis – Drugs In Development, 2024
Empower your strategies with our Cholangitis – Drugs In Development, 2024 report and make more profitable business decisions. Cholangitis refers to inflammation of the bile ducts, which are tubes that carry bile from the liver to the gallbladder and small intestine. This condition can be acute or chronic and is often caused by a bacterial infection or blockage of the bile ducts. Cholangitis can cause a range of symptoms, which may include abdominal pain, particularly in the upper right side; jaundice...
-
Product Insights
NewLiver Failure (Hepatic Insufficiency) – Drugs In Development, 2024
Empower your strategies with our Liver Failure (Hepatic Insufficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea, and loss of appetite. Since these symptoms are associated with...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Icomidocholic Acid in Liver Fibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Icomidocholic Acid in Liver Fibrosis Drug Details: Icomidocholic acid (Aramchol meglumine) is under development for...
-
Product Insights
NewInterstitial Lung Fibrosis – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SY-201 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SY-201 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SY-201 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: SY-201...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aramchol in Liver Failure (Hepatic Insufficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aramchol in Liver Failure (Hepatic Insufficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Aramchol in Liver Failure (Hepatic Insufficiency)Drug Details:Aramchol is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Belzutifan in Endometrial Cancer Drug Details:Belzutifan (Welireg), is an inhibitor of hypoxia-inducible factor-2a...